Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.71 |
| ▸ | OSBP | P22059 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 6/20 | 0.62 |
| ▸ | APP | P05067 | 4/20 | 0.62 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970232 | 1.00 | BACE1 (0.71) | BACE1PTPN1OSBPMAOBAPP | |
| SCHEMBL10494091 | 0.87 | OSBP (0.64) | BACE1PTPN1OSBPMAOBAPP | |
| SCHEMBL10494097 | 0.87 | OSBP (0.64) | BACE1PTPN1OSBPMAOBAPP | |
| Grifolin SCHEMBL21065400 | 0.83 | PTPN1 (1.00) | BACE1PTPN1OSBPMAOBAPP | |
| Grifolin SCHEMBL8589594 | 0.83 | PTPN1 (1.00) | BACE1PTPN1OSBPMAOBAPP | |
| SCHEMBL15970620 | 0.82 | MAOB (0.62) | BACE1PTPN1OSBPMAOBAPP | |
| SCHEMBL15970619 | 0.82 | MAOB (0.62) | BACE1PTPN1OSBPMAOBAPP | |
| SCHEMBL30777317 | 0.82 | BACE1 (0.58) | BACE1PTPN1OSBPMAOBAPP | |
| SCHEMBL30508969 | 0.82 | BACE1 (0.58) | BACE1PTPN1OSBPMAOBAPP | |
| SCHEMBL8024047 | 0.82 | BACE1 (0.62) | BACE1PTPN1OSBPMAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464016-B2 | Catechol derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140243424-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2720689-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | Edison Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174286-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243424-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | OPA1, PC, PCK2 | BACE1 769/4885PTPN1 3919/4885OSBP 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.